Axonal degeneration serum markers and temporal lobe atrophy in Alzheimer’s dementia continuum: a longitudinal study of plasma neurofilament light and tensor-based morphometry - Khodadadi, Amirhossein; Amirkhani, Nikan; Nouri, Zahra; Adlparvar, Tanin; Eskandari, Sanaz; Barzgar, Rezvan; Sojoudi, Pouya; Mayeli, Mahsa (medRxiv, 2024)
The plasma neurofilament light chain (NfL), an axonal cytoskeleton protein, increases in Alzheimer’s disease and was therefore proposed as a blood-based biomarker of the disease. Tensor-based morphometry (TBM) is an MR based modality that identifies local volume changes in the brain. Herein, we aimed to investigate whether plasma NfL measures can predict TBM findings derived from temporal lobe of brain in a one-year follow-up and which biomarker can predict cognitive function. A total of 480 participants with Alzheimer’s disease (AD), mild cognitive impairment (MCI), and normal cognition (CN) were found eligible for inclusion from The Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. There was a significant negative association between plasma NfL and TBM only when all subjects were pooled together at baseline (β = -0.139, P= 0.004). After one-year follow-up, 30 subjects with MCI converted to AD (MCI-AD) and others remained unchanged (CN, MCI, AD). Plasma NfL levels elevated significantly only in MCI group after one year (P<0.001). We found a significant reduction in TBM measurements at first-year compared to baseline in all groups (P<0.001 for all groups). Additionally, TBM average change rate was significantly higher in MCI-AD and AD groups (P<0.001 for both); however, plasma NfL average change rate was not significantly different between groups. TBM was significantly correlated with MMSE, MoCA, ADAS-11 and ADAS-13 scores in both MCI and AD patients at baseline and after one year, whereas plasma NfL was not. Overall, our findings indicate that plasma NfL is not reliably associated with TBM, and is less effective and sensitive than TBM in predicting dementia progression and cognitive performance. Hence, TBM reduction is not reflected in plasma NfL increment after one year follow-up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:we used The Alzheimer's Disease Neuroimaging Initiative (ADNI) database for data extraction. all interested researchers can apply for permission at https://adni.loni.usc.edu/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon applying for ADNI database. https://adni.loni.usc.edu/